Clinical Intelligence

Lightlake Therapeutics touts positive phase II results of binge eating disorder

Thursday, August 9, 2012 11:23 AM

Lightlake Therapeutics, an early stage biopharmaceutical company developing modern addiction treatments, released final data from a phase II study of its proprietary opioid antagonist naloxone nasal spray treatment for patients with binge eating disorder (BED).

More... »

FDA approves Zaltrap for metastatic colorectal cancer

Monday, August 6, 2012 12:51 PM

The FDA has approved Sanofi-Aventis’ Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

More... »

Aquapharm Biodiscovery discovers novel antibiotic compound

Monday, August 6, 2012 11:01 AM

Aquapharm Biodiscovery, a Scottish marine biotechnology company, has made a discovery in the development of next-generation antibiotics.

More... »

Array BioPharma’s ARRY-797 meets primary endpoint in osteoarthritis study

Friday, August 3, 2012 12:41 PM

Boulder, Colo.-based Array BioPharma’s phase II study of ARRY-797 met its primary endpoint osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

More... »

Pfizer releases top-line data from phase III study of tofacitinib in RA

Friday, August 3, 2012 11:24 AM

Pfizer reported today top-line results from ORAL Start (A3921069), a phase III study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

More... »

Auxilium touts top-line data from Xiaflex study in Dupuytren's contracture

Monday, July 30, 2012 11:34 AM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company based in Malvern, Penn., issued positive top-line data from its phase IIIb trial evaluating Xiaflex for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. 

More... »

FDA approves Vascepa for severe hypertriglyceridemia

Friday, July 27, 2012 10:53 AM

The FDA has approved Vascepa (icosapent ethyl) capsules as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (TG ≥ 500mg/dL), according to Amarin, a Bedminster, N.J.-based biopharmaceutical company focused on cardiovascular health.

More... »

Fast-acting TB drug cocktail shows great promise

Friday, July 27, 2012 10:48 AM

Phase II results from a novel anti-tuberculosis drug cocktail—PA-824, moxifloxacin and pyrazinamide—show the elimination of 99% of the Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), found in patients’ saliva following just two weeks of treatment.

More... »

FDA OKs Rayos for rheumatoid arthiris and more

Friday, July 27, 2012 10:31 AM

The FDA has approved Horizon Pharma’s Rayos (prednisone) delayed-release tablets (1mg, 2mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD). 

More... »

Vaccine created from patient white blood cells to target brain tumors

Friday, July 27, 2012 08:13 AM

Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of glioblastoma multiformes (GBM), the most common and aggressive type of primary brain tumor.

More... »